drugset / Trial / NCT03594461
Intense Treatment Regimen With Intravitreal Aflibercept Injection
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the safety and efficacy of intense dosing for a limited period in patients who demonstrate refractory disease on monthly IAI. Patients will be followed for 52 weeks
Timeline
- Start
- 2018-09-11
- Primary completion
- 2020-03
- Completion
- 2020-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |